Yi Zhong
Education
Ph.D. and M.S., economics, University of North Carolina at Chapel Hill; M.S., applied economics, University of Delaware; B.A., economics, Renmin University of China
Summary of Experience
Dr. Zhong specializes in the application of economic theory and econometric models to questions arising in complex health care litigation and health economics research. In a variety of health care litigation matters, including claims payment disputes; matters involving allegations of kickbacks, off-label promotion, and pay-for-delay generic entry; and commercial disputes, she has designed methods to evaluate causal relationship and assess damages and liability. She has assisted numerous affiliated experts in analysis, report preparation, and testimony in such matters. In the area of health economics research, Dr. Zhong has extensive experience in evaluating treatment effects using clinical trial and real-world data (RWD). She has designed methods to address selection in treatment initiation and confounding factors to evaluate the effects of medical treatments in different therapeutic areas. Dr. Zhong has also analyzed large clinical trial datasets, as well as government and private administrative claims and medical record datasets. She has published her health economics research in a number of peer-reviewed journals, including Muscle & Nerve, PLOS One, and Advances in Therapy.
-
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls
Muscle & Nerve, 2024
2024Iff J, Nicolae Done N, Tuttle E, Zhong Y, Wei F, Darras BT, McDonald CM, Mercuri E, Muntoni F
-
Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
Journal of Comparative Effectiveness Research, 2023
2023 -
Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy
Muscle & Nerve, 2022
2022Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, Paul X, Henricson EK, McDonald CM, CINRG-DNHS Investigators
-
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
PLOS One, 2022
2022Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ
-
Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records
Advances in Therapy, 2022
2022Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, Schrader R, CINRG DNHS Investigators